UCP1 and metabolic syndrome: In a study, it was demonstrated that the sacubitril+valsartan combination exhibited a therapeutic effect in rats with induced metabolic syndrome by increasing the levels of peroxisome proliferator-activated receptor (PPAR-γ), mammalian target of rapamycin complex 1 (mTORC1), and uncoupling protein 1 (UCP-1) in white adipose tissue (31).